摘要
特发性肺纤维化是一种预后不良的慢性纤维化性间质性肺疾病,病因不明,早期诊断、准确评估病情、及早进行临床干预,能够改善患者预后。基质金属蛋白酶-7是肺损伤后肺泡上皮细胞分泌的活性介质,对预测特发性肺纤维化的预后表现突出,也在靶向治疗上存在研究价值。基质金属蛋白酶-7区别于其他基质金属蛋白酶成员的结构及核苷酸组成的多态性,二者导致了其作用范围广泛,浓度上调高效。了解基质金属蛋白酶-7的临床应用及作用通路,探究抑制其浓度能否使特发性肺纤维化患者获益,可为早期控制疾病的发生发展提供新思路。
Idiopathic pulmonary fibrosis is a chronic fibrotic interstitial lung disease with a poor prognosis and unknown etiology.Early diagnosis,accurate disease assessment,and timely clinical intervention can improve patient’s outcomes.Matrix metalloproteinase-7 is an active mediator secreted by alveolar epithelial cells after lung injury.It is notable for its role in predicting the prognosis of idiopathic pulmonary fibrosis and has research value in targeted therapy.The structural and nucleotide composition polymorphisms that distinguish matrix metalloproteinase-7 from other matrix metalloproteinase members,lead its broad functional range and efficient up-regulation.By understanding the clinical applications and action pathways of matrix metalloproteinase-7,the study exploring whether inhibiting its concentration could benefit idiopathic pulmonary fibrosis patients could provide new insights for early disease control.
作者
郭春旭
张子璇
杜丽娟
闫莉
GUO Chunxu;ZHANG Zixuan;DU Lijuan;YAN Li(Graduate School of Hebei Medical University,Shijiazhuang 050000;Department of Pulmonary and Critical Care Medicine,Hebei General Hospital,Shijiazhuang 050000,China)
出处
《临床与病理杂志》
CAS
2024年第5期738-745,共8页
Journal of Clinical and Pathological Research
基金
河北省医学科学研究课题计划(20230300)。
